

Table 1. Detection of antiviral drug-resistant viruses in Japan during the 2018/2019 influenza season

as of November 12, 2019

	A(H1N1)pdm09						A(H3N2)						B				
	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir	Amantadine	Baloxavir	Oseltamivir	Peramivir	Zanamivir	Laninamivir
Resistant (%)	6 <sup>a</sup> (1.7%)	21 <sup>b</sup> (1.0%)	21 <sup>b</sup> (1.0%)	0	0	200 (100%)	34 <sup>c</sup> (9.5%)	0	0	0	0	155 (100%)	0	0	1 <sup>d</sup> (0.5%)	0	0
Number of viruses tested	343	2,194	2,194	365	365	200	357	353	353	353	353	155	44	192	192	192	192
Number of viruses reported	3,060						4,702						642				

Baloxavir was examined by focus reduction assay and/or PA sequencing.

NA inhibitors were examined by fluorescence-based NA-Fluor assay, chemiluminescence-based NA-XTD assay, real time RT-PCR allelic discrimination and/or NA sequencing.

Amantadine was examined by M2 sequencing.

<sup>a</sup> Patients without treatment 0

<sup>b</sup> Patients without treatment 4

<sup>c</sup> Patients without treatment 5

<sup>d</sup> Patients without treatment 1